Panakeia Launches PANProfiler Colon: AI-Powered Solution for Colon Cancer Biomarker Profiling

Panakeia, a leader in AI-driven multi-omic biomarker profiling, has unveiled its latest innovation: PANProfiler Colon. This cutting-edge software offers a complete, digital solution for profiling microsatellite instability (MSI) and mismatch repair deficiency (dMMR) using hematoxylin and eosin (H&E)-stained images of colon cancer tissue samples.

Understanding PANProfiler Colon

PANProfiler Colon leverages advanced AI and in-depth knowledge of colorectal cancer biology. The software is designed to determine MSI/dMMR status within minutes, streamlining the diagnostic process. By providing rapid and accurate results, PANProfiler Colon empowers pathologists and oncologists to make informed treatment decisions, leading to personalized care and better patient outcomes.

Why is PANProfiler Colon Important?

MSI and dMMR are crucial indicators in colorectal cancer, often linked to Lynch syndrome or hereditary nonpolyposis colorectal cancer (HNPCC). Testing for these markers is a standard in clinical practice and plays a pivotal role in guiding oncologists’ treatment plans. With PANProfiler Colon, these assessments can be completed quickly and efficiently, allowing patients to receive timely and effective care.

PANProfiler Colon: A Closer Look

The launch of PANProfiler Colon marks the second clinical product derived from Panakeia’s comprehensive PANProfiler platform. Already used in over 30 cancer types for patient screening and clinical trials, PANProfiler is currently available for research use only in the UK. PANProfiler Colon, however, is already registered for clinical use due to its UKCA marking.

This innovative solution is currently deployed in multiple hospitals across the UK, and its performance has been validated through a blinded multi-site study. The results of this study are set to be presented at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Industry Expert Opinion

Professor David Harrison MD, DSc, FRCPath, FRCPEd, FRCSEd, Professor of Pathology at the University of St Andrews, Director of iCAIRD and Consultant in NHS Lothian, commented: “PANProfiler Colon is the second profiling tool generated by Panakeia and its PANProfiler platform, the utility of which was explored by the Industrial Centre for Artificial Intelligence Research in Digital Diagnostics consortium.

“Receiving an early cancer diagnosis can vastly improve a patient’s experience and treatment outcomes. We continue to be impressed by the quality of the results generated by PANProfiler’s entirely digital molecular profiling. We look forward to continuing working with the team to uncover further time and resource saving solutions to benefit patients.”

Panakeia’s Vision for Precision Medicine

Pahini Pandya, the Founder and Chief Executive Officer of Panakeia, expressed excitement about the launch of PANProfiler Colon. She stated: “The launch of PANProfiler Colon is another key milestone for Panakeia. We are committed to making precision medicine accessible across the globe and continue to deliver on this vision by releasing our second product for use in colon cancer MSI/dMMR molecular profiling.

“Our PANProfiler suite of solutions has the potential to revolutionize precision medicine providing an end-to-end solution for biomarker profiling across the drug discovery, development, and clinical decision-making pathways.”

Evolution of the PANProfiler Platform

PANProfiler Breast was introduced before PANProfiler Colon, and both products exemplify Panakeia’s commitment to improving cancer diagnostics and treatment through advanced technology. As demonstrated by PANProfiler Colon, this platform not only accelerates the diagnostic process but also enhances the overall effectiveness and personalization of treatment decisions.

Conclusion

The launch of PANProfiler Colon represents a significant leap forward in colon cancer diagnostics. By integrating AI with pathology, Panakeia is transforming the landscape of precision medicine, ensuring that patients can receive accurate and timely information to inform their treatment journeys.

As this innovative software continues to be adopted across multiple hospitals in the UK, it promises to set a new standard in colorectal cancer diagnostics, supporting better patient outcomes and improving the efficiency of healthcare services.